New therapies for ovarian cancer

Research output: Contribution to journalArticle

Abstract

In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.

Original languageEnglish (US)
Pages (from-to)632-635
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number5S
DOIs
StatePublished - May 1 2018

Fingerprint

Ovarian Neoplasms
Guidelines
Adenosine Diphosphate Ribose
Poly Adenosine Diphosphate Ribose
Therapeutics
Mutation
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

New therapies for ovarian cancer. / Armstrong, Deborah Kay.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 5S, 01.05.2018, p. 632-635.

Research output: Contribution to journalArticle

@article{daa942eab02e46bc94bd1e047a491ea6,
title = "New therapies for ovarian cancer",
abstract = "In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.",
author = "Armstrong, {Deborah Kay}",
year = "2018",
month = "5",
day = "1",
doi = "10.6004/jnccn.2018.0034",
language = "English (US)",
volume = "16",
pages = "632--635",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5S",

}

TY - JOUR

T1 - New therapies for ovarian cancer

AU - Armstrong, Deborah Kay

PY - 2018/5/1

Y1 - 2018/5/1

N2 - In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.

AB - In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.

UR - http://www.scopus.com/inward/record.url?scp=85048307608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048307608&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0034

DO - 10.6004/jnccn.2018.0034

M3 - Article

C2 - 29784743

AN - SCOPUS:85048307608

VL - 16

SP - 632

EP - 635

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 5S

ER -